Clinical Trial Information
opportunistic infection), have recently used interleukin-2 (IL-2), or are pregnant. For more information, contact Jesse Rios, R.N., at 713.830.3050.
pancreatitis, heart disease, hemophilia, or recent hepatitis or opportunistic infection. Patients are also not eligible if they are pregnant or have received atazanavir or the other study drugs in the past. For complete details and more information, contact Mark Mall, R.N., at the Montrose Clinic (713.830.3018).
Driven by common knowledge that anti-HIV drugs are toxic, the study's planners are hoping to learn whether delayed, broken-up treatment for HIV is just as effective as immediate, uninterrupted treatment. The study will also gather information on the long-term side effects of HIV treatment and its effect on quality of life.
The study is open to anyone with HIV, male or female, who is at least 13 years old. To volunteer, you must have a T-cell count of at least 350 and you must be willing to start, stop, or change anti-HIV drug therapy, depending on the study group to which you are assigned. For the first year of the study, you will have to see the doctor once every 2 months. After that, you will see the doctor 3 times a year. For safety, you cannot volunteer for the study while you are pregnant, but you can volunteer after you have had your baby.
In Houston, this study is available at three sites: Thomas Street Clinic, the Veteran's Administration Medical Center, and Montrose Clinic. The head doctor for the study is Roberto Arduino, M.D., an associate professor of medicine at the University of Texas-Houston Medical School.
For more information, call Hilda Cuervo at 713.500.6731.
This article was provided by The Center for AIDS Information & Advocacy. It is a part of the publication HIV Treatment ALERTS!. Visit CFA's website to find out more about their activities and publications.